Lonza Group Ltd
LONNE
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
BaselCH-4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
18,686
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,126.26 | 75.19 | 0.93% |
| DAX 40 | 22,701.96 | 291.69 | 1.30% |
| Dow JONES (US) | 43,621.16 | 159.95 | 0.37% |
| FTSE 100 | 8,708.74 | 40.07 | 0.46% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,026.39 | 260.54 | -1.35% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 5,955.25 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |